2nd Annual RNAi-Based Therapeutics Summit - June 2021 - Digital Event

Kongressthemen
As investments and collaborations hit a record high, the RNAi therapeutics industry continues to rapidly expand. With RNAi drugs prevailing as a therapy with huge potential against liver diseases, exciting efforts have now turned to a wide range of other diseases, from CNS, oncology, metabolism and more. Despite the growing momentum, much needs to be addressed in terms of targeted delivery, safety, and efficiency to fully unleash the therapeutic value of RNAi drugs.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
Speakers: Greg Hinkle Vice President, Research Informatics Alnylam Pharmaceuticals, Ekkehard Leberer Senior Director, R&D Alliance Management Sanofi, Julia Alterman Senior Scientist Khvorova Lab University of Massachusetts Medical School and more

https://go.evvnt.com/733422-0?pid=4832

Herr Customer Service